Xencor, Inc. (NASDAQ:XNCR – Get Rating) CMO Allen Yang sold 3,737 shares of the stock in a transaction that occurred on Monday, December 19th. The shares were sold at an average price of $27.00, for a total transaction of $100,899.00. Following the transaction, the chief marketing officer now directly owns 63,521 shares of the company’s stock, valued at $1,715,067. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Xencor Price Performance
NASDAQ:XNCR traded down $0.13 during trading hours on Wednesday, hitting $25.71. The stock had a trading volume of 279,862 shares, compared to its average volume of 345,829. The company has a 50 day simple moving average of $28.52 and a two-hundred day simple moving average of $27.77. Xencor, Inc. has a one year low of $19.35 and a one year high of $42.30. The firm has a market capitalization of $1.54 billion, a price-to-earnings ratio of 53.56 and a beta of 0.62.
Wall Street Analyst Weigh In
A number of research firms have recently weighed in on XNCR. Canaccord Genuity Group reduced their target price on shares of Xencor from $50.00 to $48.00 in a research report on Wednesday, November 9th. Raymond James raised shares of Xencor from an “outperform” rating to a “strong-buy” rating and set a $58.00 price objective for the company in a report on Thursday, October 13th. Royal Bank of Canada cut their price objective on shares of Xencor from $40.00 to $36.00 and set an “outperform” rating for the company in a report on Tuesday, November 8th. Cowen assumed coverage on shares of Xencor in a report on Tuesday, December 6th. They issued an “outperform” rating for the company. Finally, JPMorgan Chase & Co. assumed coverage on shares of Xencor in a report on Wednesday, September 21st. They issued an “overweight” rating and a $37.00 price objective for the company. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $48.89.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the company. Bank of New York Mellon Corp boosted its holdings in Xencor by 4.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 557,087 shares of the biopharmaceutical company’s stock valued at $14,473,000 after purchasing an additional 21,300 shares during the period. Teachers Retirement System of The State of Kentucky purchased a new stake in shares of Xencor during the 3rd quarter valued at $423,000. Advisory Research Inc. raised its position in shares of Xencor by 28.9% during the 3rd quarter. Advisory Research Inc. now owns 20,967 shares of the biopharmaceutical company’s stock valued at $545,000 after buying an additional 4,698 shares in the last quarter. Balyasny Asset Management LLC purchased a new stake in shares of Xencor during the 3rd quarter valued at $478,000. Finally, BNP Paribas Arbitrage SNC raised its position in shares of Xencor by 226.3% during the 3rd quarter. BNP Paribas Arbitrage SNC now owns 61,698 shares of the biopharmaceutical company’s stock valued at $1,603,000 after buying an additional 42,789 shares in the last quarter. 99.28% of the stock is owned by institutional investors.
About Xencor
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.